20,800 Shares in Altimmune, Inc. (NASDAQ:ALT) Bought by Vontobel Holding Ltd.

Vontobel Holding Ltd. bought a new stake in shares of Altimmune, Inc. (NASDAQ:ALT) in the 4th quarter, HoldingsChannel.com reports. The firm bought 20,800 shares of the company’s stock, valued at approximately $234,000.

A number of other hedge funds also recently bought and sold shares of ALT. Barclays PLC lifted its holdings in shares of Altimmune by 62.0% in the third quarter. Barclays PLC now owns 180,409 shares of the company’s stock valued at $470,000 after purchasing an additional 69,014 shares in the last quarter. GSA Capital Partners LLP raised its position in Altimmune by 153.1% during the third quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock valued at $1,159,000 after buying an additional 269,676 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in Altimmune in the 4th quarter worth about $534,000. Dark Forest Capital Management LP grew its stake in Altimmune by 13.4% during the 3rd quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company’s stock valued at $599,000 after acquiring an additional 27,210 shares in the last quarter. Finally, Keudell Morrison Wealth Management acquired a new position in shares of Altimmune in the 3rd quarter valued at about $36,000. 78.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ALT has been the subject of several research reports. HC Wainwright decreased their price target on shares of Altimmune from $15.00 to $12.00 and set a “buy” rating for the company in a report on Monday, April 1st. The Goldman Sachs Group started coverage on shares of Altimmune in a research note on Wednesday, January 24th. They set a “neutral” rating and a $13.00 target price for the company. Finally, B. Riley restated a “buy” rating and set a $20.00 price target on shares of Altimmune in a report on Thursday, March 28th.

Altimmune Stock Performance

NASDAQ:ALT opened at $7.08 on Thursday. Altimmune, Inc. has a 52-week low of $2.09 and a 52-week high of $14.84. The firm’s 50-day moving average is $9.35 and its 200-day moving average is $7.49. The company has a market cap of $501.90 million, a price-to-earnings ratio of -4.29 and a beta of 0.05.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Wednesday, March 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.02. The firm had revenue of $0.04 million during the quarter. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. Equities analysts predict that Altimmune, Inc. will post -1.52 EPS for the current year.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.